27 Jan 2020
Esther Sammler, Clinical Programme Leader in the MRCPPU and Clinical Senior Lecturer/Honorary Consultant in the School of Medicine, has been awarded funding by Tenovus Scotland and a personal donation by Emeritus Professor Pierre Descouts (Universite de Geneve) and his wife Christine to continue research into Parkinson's disease.
15 Jan 2020
Review of the Year 2019 took place today with the Dean, Julian Blow sharing the highlights of activity within the School from 2019. The presentation closed with the annual School prizes presentation. Here are the winners: Innovator of the Year Innovator of the Year is for any member or team within SLS that demonstrably achieved scientific, technical or commercial innovation that came to fruition in 2019.
04 Nov 2019
An interdisciplinary team from across the Schools of Life Sciences and Medicine will take part in the Biotechnology YES 2019 entrepreneurial competition next month. Anna Segarra Fas (Findlay lab, MRC-PPU), Margarida Trigo (Lambert, Martin and Langston labs, Neuroscience), Saria Mansoor (Dorfmueller lab, MMB) and Tom Snelling (Cohen lab, MRC-PPU) have joined together to form the team Recycle Enterprises (RE).
31 Oct 2019
Researchers at the University of Dundee have made a discovery they believe has the potential to put the brakes on the ‘runaway train’ that is Parkinson’s disease. The team, based at the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU) in the School of Life Sciences, have discovered a new enzyme that inhibits the LRRK2 pathway. Mutations of the LRRK2 gene are the most common cause of genetic Parkinson’s.
24 Oct 2019
The annual third year PhD poster session took place this week with excellent entries from 27 students across the School. Each poster was judged by three of the 14 judges who included PIs and senior postdoctoral researchers.
01 Oct 2019
On October 1st 1969 Philip Cohen became a postdoc in Edmond Fischer’s at the University of Washington, Seattle, USA and started his research on protein phosphorylation. At that time only three protein kinases had been identified and protein phosphorylation was thought-to-be a specialised control mechanism confined to the regulation of glycogen metabolism.
29 Aug 2019
Hannah Tovell a PhD student in Dario Alessi lab working in collaboration with Claire Crafter (AstraZeneca) and Alessio Ciulli and Andrea Testa in his lab have elaborated a compound that we have termed SGK3-PROTAC1 that induces selective degradation of SGK3 protein kinase. Hannah was able to show that SGK3-PROTAC1 suppressed proliferation of ZR-75-1 and CAMA-1 cancer cell lines treated with a PI3K inhibitor (GDC0941) more effectively than could be achieved by a conventional SGK isoform inhibitor (14H), underscoring the benefit of the PROTAC approach.
31 Jul 2019
Researchers in the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC PPU) have solved one of the mysteries of cell division, a discovery which may shed light on cancer development and one day help develop new drugs to treat the disease.
02 Jul 2019
Two PhD students in the School have been selected to join Europe’s finest University students in creative and intellectual collaboration at Roche Continents 2019. The highly prestigious Roche Continents - a full week of interdisciplinary challenges and inspiration – selects only 100 students from the sciences and arts at European Universities to attend. Tom Snelling from Philip Cohen's Lab (MRC-PPU) and Margarita Kalamara from Nicola Stanley-Wall’s Lab (Molecular Microbiology) are two of those who will take part in the week of activities in Salzburg in August.
21 Jun 2019
The University of Dundee has today awarded an Honorary Doctorate to Dr Samantha Budd Haeberlein who is Vice President of Late Stage Clinical Development at Biogen. Samantha is a distinguished graduate of Dundee having obtained a First Class Honours Degree in Biochemistry in 1994 and then completing a PhD in 1997 under the supervision of David Nicholls FRS on the bioenergetics of neurons. Since then Samantha has flourished in the pharmaceutical industry over the last 20 years and emerged as a global leader in developing effective therapies against Alzheimer’s disease.